Sarah Reiffenberger, MD
Family Medicine · Watertown, SDNPI 1700844198
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $14.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$570
- Lilly USA, LLC$525
- Daiichi Sankyo Inc.$261
- Amgen$233
- Johnson & Johnson$227
- AbbVie$208
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,58398%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 53 | $570 |
| Lilly USA, LLC | 39 | $525 |
| Daiichi Sankyo Inc. | 17 | $261 |
| Amgen | 15 | $233 |
| Johnson & Johnson | 26 | $227 |
| AbbVie | 10 | $208 |
| Astellas Pharma US Inc | 7 | $176 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $148 |
| Grifols USA, LLC | 8 | $136 |
| Novo Nordisk | 9 | $129 |
| Boehringer Ingelheim | 9 | $128 |
| Abbott | 7 | $111 |
| AstraZeneca | 2 | $110 |
| Bayer | 5 | $92 |
| Eisai Inc. | 4 | $70 |
| Amarin Pharma, Inc. | 5 | $64 |
| Merck | 4 | $55 |
| Novartis | 4 | $50 |
| Exact Sciences | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Actelion Pharmaceuticals US, Inc. | 2 | $29 |
| Dexcom, Inc. | 2 | $26 |
| Abiomed | 1 | $26 |
| Organon | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Medtronic | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| BETA Bionics, Inc. | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
How this compares
$3,672 in reported general payments places this provider in the 95th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $80,699 |
| XareltoRivaroxaban | 39 | $31,556 |
| JardianceEmpagliflozin | 31 | $23,508 |
| MounjaroTirzepatide | 17 | $19,814 |
| JanuviaSitagliptin Phosphate | 28 | $18,630 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $16,158 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $14,986 |
| OzempicSemaglutide | 11 | $13,450 |
| FarxigaDapagliflozin Propanediol | 15 | $9,741 |
| MyrbetriqMirabegron | 23 | $9,057 |
| Serevent DiskusSalmeterol Xinafoate | 12 | $5,116 |
| Levothyroxine Sodium | 571 | $4,253 |
| Potassium Chloride | 176 | $3,303 |
| PremarinEstrogens, Conjugated | 11 | $3,268 |
| Metoprolol Succinate | 213 | $3,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $570 | $83,967111 claims |
| Johnson & JohnsonXarelto | $227 | $31,55639 claims |
| Boehringer IngelheimJardiance | $128 | $23,50831 claims |
| Lilly USA, LLCMounjaro | $525 | $19,81417 claims |
| MerckJanuvia | $55 | $18,63028 claims |
| GSKTrelegy Ellipta | $16 | $14,98624 claims |
| Novo NordiskOzempic | $129 | $13,45011 claims |
| AstraZenecaFarxiga | $110 | $9,74115 claims |
| Astellas Pharma US IncMyrbetriq | $176 | $9,05723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Watertown
- Jonathan McAreaveyWatertown$5K
- Aaron ShivesWatertown$5K
- Daniel ReiffenbergerWatertown$3K
- Jessica HornWatertown$3K
- Joseph OroWatertown$2K
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.